Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1458"

Predicate	Value (sorted: none)
rdf:type	?:Evidence
rdf:type	?:Item
rdfs:label	"evidence_1405"
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:Evidence_assump_list_id	"243"
?:Evidence_enzyme_system	""
?:claim_assumed_valid_for_evidence_application_evidence_1405	?:paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6
dc:creator	"boycer"
dc:date	"09/24/2009 15:49:33"
?:content	"CYP2D6 Inhibitors The potent CYP2D6 inhibitor, paroxetine (20 mg once daily), increases ranolazine concentrations 1.2-fold. No dose adjustment of Ranexa is required in patients treated with CYP2D6 inhibitors."
rdfs:seeAlso	?:lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ ranolazine_substrate_of_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1405 }

Context graph